Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22036Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Skapinakis, P. | en |
| dc.contributor.author | Bakola, E. | en |
| dc.contributor.author | Salanti, G. | en |
| dc.contributor.author | Lewis, G. | en |
| dc.contributor.author | Kyritsis, A. P. | en |
| dc.contributor.author | Mavreas, V. | en |
| dc.date.accessioned | 2015-11-24T19:20:23Z | - |
| dc.date.available | 2015-11-24T19:20:23Z | - |
| dc.identifier.issn | 1471-2377 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22036 | - |
| dc.rights | Default Licence | - |
| dc.subject | Depressive Disorder/*complications/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Parkinson Disease/*complications/*drug therapy | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Serotonin Uptake Inhibitors/*therapeutic use | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1186/1471-2377-10-49 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20565960 | - |
| heal.identifier.secondary | http://www.biomedcentral.com/1471-2377/10/49 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for the treatment of depression in patients with Parkinson's Disease (PD) but data on their efficacy are controversial. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials to investigate the efficacy and acceptability of SSRIs in the treatment of depression in PD. RESULTS: Ten studies were included. In the comparison between SSRIs and Placebo (n = 6 studies), the combined risk ratio (random effects) was 1.08 (95% confidence interval: 0.77 - 1.55, p = 0.67). In the comparison between SSRIs and Tricyclic Antidepressants (TCAs) (n = 3 studies) the combined risk ratio was 0.75 (0.39 - 1.42, p = 0.37). An acceptability analysis showed that SSRIs were generally well tolerated. CONCLUSIONS: These results suggest that there is insufficient evidence to reject the null hypothesis of no differences in efficacy between SSRIs and placebo in the treatment of depression in PD. Due to the limited number of studies and the small sample sizes a type II error (false negative) cannot be excluded. The comparison between SSRIs and TCAs is based on only three studies and further trials with more pragmatic design are needed. | en |
| heal.journalName | BMC Neurol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Skapinakis-2010-efficacy and acceptability.pdf | 2.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
